(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.29%) $0.934
(0.56%) $11.01
(0.11%) $0.800
(0.00%) $92.17
Live Chart Being Loaded With Signals
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally...
Stats | |
---|---|
今日成交量 | 713 845 |
平均成交量 | 724 103 |
市值 | 132.07B |
EPS | $0 ( 2024-02-13 ) |
Last Dividend | $1.621 ( 2023-03-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | 34.86 |
ATR14 | $0.0970 (0.04%) |
音量 相关性
CSL Ltd 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
CSL Ltd 相关性 - 货币/商品
CSL Ltd 财务报表
Annual | 2023 |
营收: | $19.59B |
毛利润: | $9.47B (48.33 %) |
EPS: | $6.92 |
FY | 2023 |
营收: | $19.59B |
毛利润: | $9.47B (48.33 %) |
EPS: | $6.92 |
FY | 2022 |
营收: | $14.47B |
毛利润: | $7.68B (53.05 %) |
EPS: | $6.63 |
FY | 2021 |
营收: | $10.27B |
毛利润: | $5.80B (56.49 %) |
EPS: | $5.22 |
Financial Reports:
No articles found.
CSL Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$1.758 (N/A) |
$0 (N/A) |
$1.621 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0167 | 1994-11-08 |
Last Dividend | $1.621 | 2023-03-09 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 59 | -- |
Total Paid Out | $28.07 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.48 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 7.26 | |
Div. Directional Score | 9.64 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
NGI.AX | Ex Dividend Junior | 2023-09-20 | Annually | 0 | 0.00% | |
WTC.AX | Ex Dividend Knight | 2023-09-08 | Semi-Annually | 0 | 0.00% | |
FEX.AX | Ex Dividend Knight | 2023-09-01 | Annually | 0 | 0.00% | |
PMC.AX | Ex Dividend Junior | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
ARB.AX | Ex Dividend Knight | 2023-10-05 | Semi-Annually | 0 | 0.00% | |
IDX.AX | Ex Dividend Junior | 2023-08-31 | Semi-Annually | 0 | 0.00% | |
SCG.AX | Ex Dividend Junior | 2023-08-17 | Annually | 0 | 0.00% | |
CAR.AX | Ex Dividend Knight | 2023-09-15 | Semi-Annually | 0 | 0.00% | |
MAD.AX | Ex Dividend Knight | 2023-09-19 | Semi-Annually | 0 | 0.00% | |
TER.AX | Ex Dividend Junior | 2023-06-08 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.180 | 1.500 | 6.41 | 9.61 | [0 - 0.5] |
returnOnAssetsTTM | 0.0696 | 1.200 | 7.68 | 9.21 | [0 - 0.3] |
returnOnEquityTTM | 0.156 | 1.500 | 9.38 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.450 | -1.000 | 5.50 | -5.50 | [0 - 1] |
currentRatioTTM | 2.15 | 0.800 | 4.25 | 3.40 | [1 - 3] |
quickRatioTTM | 0.971 | 0.800 | 9.00 | 7.20 | [0.8 - 2.5] |
cashRatioTTM | 0.216 | 1.500 | 9.91 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.282 | -1.500 | 5.30 | -7.95 | [0 - 0.6] |
interestCoverageTTM | 6.97 | 1.000 | 8.53 | 8.53 | [3 - 30] |
operatingCashFlowPerShareTTM | 8.34 | 2.00 | 7.22 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.59 | 2.00 | 8.21 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.612 | -1.500 | 7.55 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.484 | 1.000 | 5.26 | 5.26 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.244 | 1.000 | 7.12 | 7.12 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.261 | 1.000 | 9.66 | 9.66 | [0.2 - 2] |
assetTurnoverTTM | 0.388 | 0.800 | -0.748 | -0.599 | [0.5 - 2] |
Total Score | 12.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 34.66 | 1.000 | 6.60 | 0 | [1 - 100] |
returnOnEquityTTM | 0.156 | 2.50 | 9.60 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.59 | 2.00 | 8.80 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.393 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 8.34 | 2.00 | 7.22 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.450 | 1.500 | 5.50 | -5.50 | [0 - 1] |
pegRatioTTM | 7.92 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.190 | 1.000 | 7.75 | 0 | [0.1 - 0.5] |
Total Score | 7.26 |
CSL Ltd
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。